CSIMarket
 
Taiwan Liposome Company Ltd   (TLC)
Other Ticker:  
 
 
Price: $0.0000 $0.00 %
Day's High: 0.00 Week Perf:
Day's Low: $ 0.00 30 Day Perf:
Volume (M): 0 52 Wk High: $ 0.00
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) 79
 Employees 200
 Revenues (TTM) (Millions $) 4
 Net Income (TTM) (Millions $) -35
 Cash Flow (TTM) (Millions $) 36
 Capital Exp. (TTM) (Millions $) 1

Taiwan Liposome Company Ltd
Taiwan Liposome Company (TLC) Ltd is a fully-integrated specialty pharmaceutical company located in Taiwan that focuses on the research, development, manufacturing, and commercialization of liposome-based drugs. They have successfully developed innovative liposome-based drug delivery systems, and their technologies have been recognized as one of the world's leading drug delivery platforms.

TLC was established in 1997 and has since made significant advancements in the field of drug delivery systems. They have a team of experienced scientists and researchers who continuously strive to develop new and better liposome-based drug products to serve the unmet medical needs of patients. The company has strong capabilities in research and development, quality control, and production, which enable them to ensure the highest level of quality and reliability for their products.

TLCes liposome-based drug delivery system is a well-established technology that has exceptional potential for drug development. The drug delivery system is designed to improve the therapeutic efficacy and safety of drug molecules by encapsulating them in liposomes, which are tiny spheres made of lipids. This innovative drug delivery system has shown effectiveness in improving the circulation time of drugs, targeting specific tissues, reducing the toxicity and side effects of drugs, and improving the bioavailability of poorly soluble drugs.

TLC has developed several unique liposome-based products that have been approved by regulatory agencies such as the US FDA and the Taiwan FDA for various indications. These products include Doxil, an anticancer drug for the treatment of ovarian and breast cancer, and Lipusu, a fungal infection drug for the treatment of systemic candidiasis. They also have a well-developed pipeline of liposome-based products for the treatment of cancer, infectious diseases, and other therapeutic areas.

Apart from their drug development capabilities, TLC has also established themselves as a reliable and professional CDMO (Contract Development and Manufacturing Organization) with a state-of-the-art manufacturing facility. Their manufacturing capabilities support small-scale and large-scale production to meet the needs of their partners and clients globally. The company complies with regulatory standards such as cGMP, ensuring the highest level of quality and safety of their products.

In conclusion, Taiwan Liposome Company Ltd is a highly innovative specialty pharmaceutical company that has a proven track record in developing liposome-based drug delivery systems. Their technology has been recognized as one of the world's leading drug delivery platforms, and they have a strong pipeline of products, including some that have already received regulatory approval, showcasing tremendous potential for the future. Their manufacturing capabilities also position them as an exceptional CDMO, delivering high-quality drugs to clients globally.


   Company Address: 11F-1, No. 3 Yuanqu Street Taipei City 11503
   Company Phone Number: 2 2655 7377   Stock Exchange / Ticker: NASDAQ TLC
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Leap Therapeutics Inc

Leap Therapeutics Inc Posts Operating Deficit of $14.82 Million in Latest Financial Report

Leap Therapeutics Inc, a major pharmaceutical preparations company, recently reported its financial results for the October to December 31, 2023 reporting season. While shareholders had not anticipated any significant changes, they were disappointed to observe an operating deficit of $14.82 million during this period. This represents a decline compared to the fourth quarter of 2022, when the operating deficit stood at $13.943 million.
Furthermore, the company recorded a shortfall of $12.465 million, a significant increase from the previous year's $12.102 million deficit. These figures highlight the challenging environment faced by Leap Therapeutics Inc during the specified timeframe.

Xbiotech Inc

XBITsn Holds Steady Revenue in Fourth Quarter of 2023

Xbiotech Inc., a leading biotechnology company, recently released its financial results for the fiscal period ending December 31, 2023. The company reported a loss of $0.15 per share, compared to $0.10 per share the previous year, while Income per Share improved from $0.24 to $0.00 per share from the previous quarter. Despite the losses, the company remains optimistic about its future growth prospects.
One interesting fact from the financial report is that Xbiotech Inc. realized a net shortfall of $4.635 million, which is higher than the $3.203 million reported a year ago. Additionally, the company also noted a shortfall of $24.56 million for the financial period 2023. Despite these challenges, the company is committed to innovation and advancing the frontiers of medical science.

Acurx Pharmaceuticals Inc

Acurx Pharmaceuticals Inc Faces Stock Plunge and Financial Contraction in Fiscal Fourth Quarter of 2023

Acurx Pharmaceuticals Inc, a Major Pharmaceutical Preparations company, has seen a significant drop in its stock price over the past year. The stock has dropped by -21.13% compared to a year ago, and by -35.48% in the past 90 days. Currently trading on the NASDAQ, the stock is -7.5% below its 52-week average.
The company recently reported its financial results for the period ending December 31, 2023, and shareholders have expressed concerns about the top-line performance. The operating shortfall for Acurx Pharmaceuticals Inc was at $-5.11459 million, which represents a contraction from $-3.260511 million in the fourth quarter of 2022. Analysts are closely watching to see if the company can improve its revenue numbers in the coming quarters.

Soligenix Inc

Soligenix Inc Narrows Fourth Quarter Shortfall 2.

As a financial journalist for the , I have been closely following the recent financial results of Major Pharmaceutical Preparations company, Soligenix Inc. The company's performance in the October to December 31, 2023 period has shown some improvement compared to the previous year.
In the fourth quarter of 2023, Soligenix Inc reported a net shortfall of $-1.820 million, a significant improvement from the $-11.901 million deficit in the same quarter a year ago. The company also managed to reduce its shortfall per share to $-0.17 from $-4.14 in the previous year, indicating progress in their financial performance.
Despite the positive changes, Soligenix Inc's revenue deteriorated by -11.55% from $0.95 million in the previous year. However, in the recent quarter, revenue surged by 87.682% from $0.13 million in the prior quarter, showing a promising trend for the company's future financial performance.

Eterna Therapeutics Inc

Eterna Therapeutics Inc Reports Revenue of $0.017 Million in Q4 2023 Financial Results

In the fourth quarter of 2023, Eterna Therapeutics Inc, a major pharmaceutical preparations company, disclosed revenue of $0.017 million, marking a slight increase from the previous year. However, the company also reported a net deficit of $-6.153 million for the same quarter, which was larger than the deficit of $-4.490 million in the previous year. This increase in deficit is concerning to analysts, especially as the level of accounts receivable has declined to $0.4 million, indicating a potential slowdown in demand for the company's products.
Furthermore, Eterna Therapeutics Inc indicated a net deficit of $-21.67 million for the fiscal year 2023, along with revenue of $0.07 million. Despite these challenges, the company has managed to decrease its deficit per share to $-4.08 from $-8.06 in the preceding fiscal year, showing some improvement in its financial performance.






 

Taiwan Liposome Ltd's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com